Rallybio Co. (NASDAQ:RLYB) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Rallybio Co. (NASDAQ:RLYB) have been given an average rating of “Moderate Buy” by the six ratings firms that are presently covering the company, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $9.75.

A number of equities analysts have recently weighed in on RLYB shares. Evercore ISI reissued an “outperform” rating and issued a $15.00 price target on shares of Rallybio in a report on Monday, August 26th. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Rallybio in a report on Friday, November 22nd.

Hedge Funds Weigh In On Rallybio

A number of large investors have recently bought and sold shares of RLYB. Hsbc Holdings PLC bought a new stake in shares of Rallybio during the second quarter valued at about $25,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Rallybio during the 2nd quarter worth about $61,000. Acadian Asset Management LLC lifted its stake in shares of Rallybio by 116.3% in the 2nd quarter. Acadian Asset Management LLC now owns 67,695 shares of the company’s stock worth $89,000 after acquiring an additional 36,401 shares during the period. Almitas Capital LLC bought a new position in shares of Rallybio in the second quarter valued at approximately $135,000. Finally, Geode Capital Management LLC increased its stake in shares of Rallybio by 11.4% during the third quarter. Geode Capital Management LLC now owns 244,986 shares of the company’s stock valued at $287,000 after acquiring an additional 24,980 shares during the period. Institutional investors own 90.34% of the company’s stock.

Rallybio Stock Performance

Shares of NASDAQ RLYB opened at $1.13 on Tuesday. Rallybio has a one year low of $0.95 and a one year high of $3.46. The firm has a market capitalization of $46.88 million, a P/E ratio of -0.71 and a beta of -1.67. The company’s fifty day moving average is $1.06 and its two-hundred day moving average is $1.24.

Rallybio Company Profile

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.